Literature DB >> 2013388

Redevelopment of hepatitis B surface antigen after renal transplantation.

P Marcellin1, E Giostra, M Martinot-Peignoux, M A Loriot, M L Jaegle, P Wolf, C Degott, F Degos, J P Benhamou.   

Abstract

A patient with chronic hepatitis B virus (HBV) and chronic renal failure received a renal transplantation. Hepatitis B surface antigen (HBsAg) disappeared, and antibodies to HBsAg appeared 10 months before transplantation. Liver tests showed no abnormality at transplantation. Six months later, chronic hepatitis reactivated, antibodies to HBsAg disappeared, and HBsAg reappeared. Hepatitis B virus DNA was demonstrated with polymerase chain reaction in the serum collected before transplantation. This observation suggests that low level HBV replication was present before transplantation despite the absence of detectable HBsAg and was reactivated under immunosuppressive therapy after transplantation.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2013388

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


  12 in total

1.  Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.

Authors:  Arpan Patel; Suna Yapali; Anna S F Lok
Journal:  Hepatol Int       Date:  2015-08-14       Impact factor: 6.047

2.  Management of hepatitis B in developing countries.

Authors:  Zaigham Abbas; Adeel R Siddiqui
Journal:  World J Hepatol       Date:  2011-12-27

3.  Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.

Authors:  Charlie Laohapand; Emvalee Arromdee; Tawesak Tanwandee
Journal:  Hepatol Int       Date:  2015-01-15       Impact factor: 6.047

Review 4.  Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B.

Authors:  Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2013-10-17

5.  Kidney transplantation in patients with chronic hepatitis B virus infection: is the prognosis worse?

Authors:  T I Huo; W C Yang; J C Wu; K L King; C C Loong; C Y Lin; F Y Chang; S D Lee
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

6.  Long-lasting memory T cell responses following self-limited acute hepatitis B.

Authors:  A Penna; M Artini; A Cavalli; M Levrero; A Bertoletti; M Pilli; F V Chisari; B Rehermann; G Del Prete; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

Review 7.  Pathogenesis of occult chronic hepatitis B virus infection.

Authors:  Rocio Aller de la Fuente; María L Gutiérrez; Javier Garcia-Samaniego; Conrado Fernández-Rodriguez; Jose Luis Lledó; Gregorio Castellano
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

Review 8.  Management of occult hepatitis B virus infection: an update for the clinician.

Authors:  José Luis Lledó; Conrado Fernández; María Luisa Gutiérrez; Sara Ocaña
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

9.  Hepatic encephalopathy associated with cancer or anticancer therapy.

Authors:  Kaspar J Willson; Louise M Nott; Vy T Broadbridge; Timothy Price
Journal:  Gastrointest Cancer Res       Date:  2013-01

Review 10.  Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection.

Authors:  Peiman Habibollahi; Saeid Safari; Nasser E Daryani; Seyed M Alavian
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.